Treos Bio
A clinical-stage biotech company using data science and proprietary biomarkers to develop precision peptide immunotherapies.
As of Q2 2024, Treos has conducted three clinical trials in the US and the EU of its lead candidate, PolyPEPI1018. It is an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer. Treos has also completed preclinical development of additional off-the-shelf immunotherapies for ovarian, breast, bladder, gastric, lung cancers, and melanoma.
The company is also developing off-the-shelf immunotherapies personalized to an individual patient’s HLA genotype for several types of solid tumors.
Latest Treos Bio News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze